Details of the Drug Combination

General Information of Drug Combination (ID: DCWCQQE)

Drug Combination Name
Insulin-lispro Insulin-glargine
Indication
Disease Entry Status REF
Diabetes Mellitus, Type 2 Phase 1 [1]
Component Drugs Insulin-lispro   DM4O90W Insulin-glargine   DMR4HIW
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Insulin-lispro
Disease Entry ICD 11 Status REF
Diabetic complication 5A2Y Approved [2]
Non-insulin dependent diabetes 5A11 Approved [3]
Type-1 diabetes 5A10 Approved [4]
Insulin-lispro Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Insulin receptor (INSR) TTCBFJO INSR_HUMAN Binder [10]
------------------------------------------------------------------------------------
Indication(s) of Insulin-glargine
Disease Entry ICD 11 Status REF
Diabetic complication 5A2Y Approved [5]
Non-insulin dependent diabetes 5A11 Approved [6]
Malaria 1F40-1F45 Phase 3 [7]
Type-1 diabetes 5A10 Phase 3 [8]
Type-2 diabetes 5A11 Application submitted [9]
Insulin-glargine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Insulin (INS) TTZOPHG INS_HUMAN Modulator [11]
------------------------------------------------------------------------------------
Insulin-glargine Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Insulin receptor (INSR) OTTY341H INSR_HUMAN Increases Phosphorylation [12]
Insulin-like growth factor 1 receptor (IGF1R) OTXJIF13 IGF1R_HUMAN Increases Phosphorylation [12]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Diabetes Mellitus, Type 1 DCYNJ5C N. A. Phase 1 [13]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01215955) Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes
2 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3 Diabetes mellitus: complications and therapeutics. Med Sci Monit. 2006 Jul;12(7):RA130-47. Epub 2006 Jun 28.
4 Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes. N Engl J Med. 2022 Sep 29;387(13):1161-1172.
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7572).
6 Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022 Feb 8;327(6):534-545.
7 ClinicalTrials.gov (NCT02059161) A Study of the Safety and Efficacy of MK-1293 Compared to Lantus in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003). U.S. National Institutes of Health.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10 Hope for insulin mimetic oral antidiabetic drugs. Eur J Endocrinol. 1999 Dec;141(6):561-2.
11 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
12 IR and IGF-1R expression affects insulin induced proliferation and DNA damage. Toxicol In Vitro. 2017 Mar;39:68-74. doi: 10.1016/j.tiv.2016.11.011. Epub 2016 Nov 22.
13 ClinicalTrials.gov (NCT01454284) A Study in Participants With Type I Diabetes Mellitus